A Conversation With FDA Interventional Cardiology Reviewer Andrew Farb
This article was originally published in The Gray Sheet
Executive Summary
When FDA needed experts to guide its response to the emerging drug-eluting stent thrombosis issue in 2006, it was lucky to find it already had a cardiovascular pathologist experienced with implantable devices on its review staff
You may also be interested in...
Upcoming FDA Guidance Will Offer New Thinking On Drug-Eluting Stents
FDA plans to issue a guidance document on drug-eluting stents in the next several months to communicate new premarket and postmarket recommendations for the heavily scrutinized products
WHO Examines Ethical Criteria For Human Challenge Trials Ahead Of Next Health Emergency
The World Health Organization is looking to finalize its guidance on the ethical criteria that should be applied to studies that involve deliberately infecting healthy individuals to speed up research.
Irish Body Sets Out Five-Year Vision Strategy For Off-Patent Sector
With a focus on drug accessibility, supply chain resilience, and a balanced approach to sustainability, Medicines for Ireland “calls to action” with its five-year plan.